Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.070
0.00 (0.00%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Cocrystal Pharma Employees
Cocrystal Pharma had 10 employees as of December 31, 2025. The number of employees decreased by 1 or -9.09% compared to the previous year. That makes Cocrystal Pharma the 40,127th largest employer in the world and 6,046th in the United States.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
$33,000
Profits / Employee
-$993,800
Market Cap
20.61M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | -1 | -9.09% |
| Dec 31, 2024 | 11 | -1 | -8.33% |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| aTyr Pharma | 60 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| Atossa Therapeutics | 16 |
| Psyence Biomedical | 12 |
| NewcelX | 12 |
| Quoin Pharmaceuticals | 6 |
| Akari Therapeutics, | 6 |
COCP News
- 4 weeks ago - Cocrystal Pharma doses last subject in norovirus challenge study - TheFly
- 4 weeks ago - Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment - GlobeNewsWire
- 7 weeks ago - Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors - GlobeNewsWire
- 2 months ago - Cocrystal Pharma announces $5M investment from Opko Health - TheFly
- 2 months ago - Cocrystal Pharma announces $5M private placement with Opko Health - TheFly
- 2 months ago - Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - GlobeNewsWire
- 4 months ago - Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds - TheFly
- 4 months ago - Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - GlobeNewsWire